Table 3.
The treatment characteristics of the included studies.
| Author and year | Patients Analyzed for PSA Decline (n) | Dose | Cycles of Therapy (Median, Range) | Follow-Up (wk) | Any PSA Decline (%) | PSA Decline >50% |
|---|---|---|---|---|---|---|
| Kratochwil et al. (12) | 38 | 100 KBq/kgBW | 1–3 | 8 | 33/38 (87) | 24/38 (63) |
| Sathekge et al. (13) | 73 | 4–8 MBq/cycle | 3 (1–8) | 8 | 60/73 (83) | 51/73 (70) |
| van der Doelen et al. (14) | 13 | 6–8 MBq/cycle | 3 (1–4) | 8 | NR | 9/13 (69) |
| Satapathy et al. (15) | 11 | 100 KBq/kgBW | 2 (1–4) | 8–12 | NR | 5/11 (46) |
| Feuerecker et al. (16) | 26 | 9 MBq/cycle | 2 (1–6) | 8 | 23/26 (88) | 17/26 (65) |
| Sen et al. (17) | 38 | 100 KBq/kgBW | 2 (2–5) | 8 | 33/38 (87) | 25/38 (66) |
NR, not reported; BW, body weight; PSA, prostate-specific antigen.